Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 16/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134517 | 0.92 | TP53 (0.50) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6134854 | 0.85 | TP53 (0.45) | CA12CA1CA2CA9MAPT | |
| SCHEMBL7313043 | 0.84 | TP53 (0.50) | CA12CA1CA2CA9F2RL3 | |
| SCHEMBL6132626 | 0.84 | TP53 (0.46) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6133896 | 0.84 | TP53 (0.42) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6134575 | 0.83 | TP53 (0.43) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6135271 | 0.83 | CSNK2A2 (0.53) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6135134 | 0.83 | TP53 (0.44) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6134879 | 0.83 | HDAC3 (0.51) | CA12CA1CA2CA9MAPT | |
| SCHEMBL6134933 | 0.82 | HRH3 (0.48) | CA12CA1CA2CA9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | CA12 3234/4885CA1 2356/4885CA2 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.